• ONL Therapeutics closes $46.9 million in financing

    3 days ago - By Healio

    ONL Therapeutics has closed its second tranche of Series B financing, which totaled $46.9 million, according to a press release.
    In addition, the company has advanced its lead candidate, ONL1204 ophthalmic solution, into indications of open-angle glaucoma and geographic atrophy associated with age-related macular degeneration.
    ONL1204 is “a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions,” the release said. The financing will enable the
    Read more ...